This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

AbbVie Presents Results From Phase I Study Of Investigational Oncology Compound ABT-199 At American Society Of Clinical Oncology Annual Meeting

NORTH CHICAGO, Ill., June 3, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a Phase I study of ABT-199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the most common leukemia in the United States, and relapsed/refractory non-Hodgkin's lymphoma (NHL).  Results from the study were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO).

This Phase I, open-label, multicenter, international trial was designed to assess the safety, determine the maximum tolerated dose and recommended Phase II dose, and evaluate the pharmacokinetics of ABT-199 in patients with relapsed/refractory CLL and NHL. Secondary objectives included preliminary efficacy, including objective response rate (ORR), duration of response, time to progression, progression-free survival (PFS) and overall survival (OS). 

"The ABT-199 data underscore AbbVie's commitment to the development of treatments for some of the hardest-to-treat cancers like CLL and NHL," said Gary Gordon, M.D., divisional vice president, oncology clinical development, AbbVie. "Early trials of ABT-199 have shown the compound's potential in these hematological malignancies, which support the continuation of its clinical development program."

CLL ArmAs of April 2013, 56 patients have enrolled in the CLL arm of the Phase I trial, and 40 patients are currently active. Study participants were given a single oral dose of ABT-199, followed by six days without medication, before continuous once-daily dosing. Due to concerns over tumor lysis syndrome (TLS), the initial dose was reduced and daily dosing was modified. Single-agent activity was observed in the trial and warrants further single-agent and combination trials evaluating ABT-199 in patients with CLL. Dose and schedule evaluation will continue.

"While still early in the development process, the activity with ABT-199 as a single-agent supports further investigation of the compound in patients with CLL, a patient population with a high unmet need for new treatment options," said Matthew Davids, M.D., attending physician in the Lymphoma Program of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute, and Instructor in Medicine at Harvard Medical School.

During the study, 13 patients discontinued treatment; seven due to progression of disease and six for other reasons (two due to TLS, two for other illnesses, one for thromboembolic event and one consent withdrawal). The most common non-hematological adverse events (AEs) during the study were nausea (36%), diarrhea (30%), fatigue (25%), upper respiratory tract infection (23%) and cough (16%). In the first study group, TLS occurred in all three of the enrolled patients; once the modified dosing schedule was utilized, three of the 53 patients experienced adverse events of TLS. One fatal adverse event occurred in a patient with laboratory evidence of TLS.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs